Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.53 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.53 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.53 |
| ▸ | KLK7 | P49862 | 2/20 | 0.52 |
| ▸ | KLK5 | Q9Y337 | 2/20 | 0.52 |
| ▸ | SYK | P43405 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | MMP1 | P03956 | 1/20 | 0.51 |
| ▸ | MMP3 | P08254 | 1/20 | 0.51 |
| ▸ | MMP9 | P14780 | 1/20 | 0.51 |
| ▸ | CTSL | P07711 | 1/20 | 0.50 |
| ▸ | CTSS | P25774 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.49 |
| ▸ | CA2 | P00918 | 1/20 | 0.49 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.49 |
| ▸ | CTSK | P43235 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19971941 | 1.00 | SIRT2 (0.53) | SIRT2SIRT1SIRT3KLK7KLK5 | |
| SCHEMBL19971942 | 1.00 | SIRT2 (0.53) | SIRT2SIRT1SIRT3KLK7KLK5 | |
| SCHEMBL19971949 | 1.00 | SIRT2 (0.53) | SIRT2SIRT1SIRT3KLK7KLK5 | |
| SCHEMBL13599694 | 0.93 | MAPT (0.56) | SIRT2SIRT1SIRT3KLK7KLK5 | |
| SCHEMBL19295560 | 0.92 | SIRT2 (0.60) | SIRT2SIRT1SIRT3KLK7KLK5 | |
| SCHEMBL21900170 | 0.92 | SIRT2 (0.60) | SIRT2SIRT1SIRT3KLK7KLK5 | |
| SCHEMBL21900169 | 0.92 | SIRT2 (0.60) | SIRT2SIRT1SIRT3KLK7KLK5 | |
| SCHEMBL8246040 | 0.91 | MAPT (0.53) | SIRT2SIRT1SIRT3KLK7KLK5 | |
| SCHEMBL8245686 | 0.91 | MAPT (0.53) | SIRT2SIRT1SIRT3KLK7KLK5 | |
| SCHEMBL5309738 | 0.91 | MAPT (0.53) | SIRT2SIRT1SIRT3KLK7KLK5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10858389-B2 | Solution phase method for preparing etelcalcetide | AMGEN INC. (US) | 2020-12-08 | — | — | US | disclosed |
| EP-3274360-B1 | SOLUTION PHASE METHOD FOR PREPARING ETELCALCETIDE | AMGEN INC (US) | 2020-05-06 | — | — | EP | disclosed |
| US-20180079777-A1 | SOLUTION PHASE METHOD FOR PREPARING ETELCALCETIDE | AMGEN INC. | 2018-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10858389-B2 | Solution phase method for preparing etelcalcetide | PTH1R, CALCR, SOST | SIRT2 4640/4885SIRT1 4738/4885SIRT3 4711/4885 |
| US-20180079777-A1 | SOLUTION PHASE METHOD FOR PREPARING ETELCALCETIDE | PTH1R, CALCR, SOST | SIRT2 4640/4885SIRT1 4738/4885SIRT3 4711/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.